News

Noticias

Marcelo Rebelo de Sousa honours BIAL's longest-serving employee in the year of the company’s centenary

President of the Republic visits Portuguese pharmaceutical company's factory as part of the conference celebrating its 100th anniversary

Read

BIAL launches KYNMOBI® in Germany

The first sublingual therapy for the on-demand treatment of OFF episodes in Parkinson’s disease

Read

BIAL appoints Pierluigi Antonelli as Non-Executive Board Member

BIAL appoints Pierluigi Antonelli as Non-Executive Board Member

Read

BIAL celebrates its centenary in 2024

BIAL celebrates its centenary in 2024. Initiatives planned throughout the year will establish relationships with employees, partners and the community.

Read

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Read

BIAL to discuss scientific advances in Epilepsy

BIAL to discuss scientific advances in Epilepsy

Read

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156

BIAL R&D Announces First Patient Dosed in its Phase 2 Clinical Trial of BIA 28-6156 to Treat Parkinson’s Disease Patients With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene.

Read

BIAL Appoints Melanie Lee As Non-Executive Board Member

BIAL Appoints Melanie Lee As Non-Executive Board Member

Read

BIAL appoints Max Bricchi as Chief Commercial Officer

BIAL has announced the appointment of Max Bricchi as Chief Commercial Officer (CCO) and Executive Board member.

Read